Agenda

Return

C. 60

To:	Board of Supervisors
From:	Anna Roth, Health Services Director
Date:	September 20, 2022

Contra

Costa

County

Subject:

Purchase Order with Polymedco, Inc.

APPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR	RECOMMENDATION OF BOARD COMMITTEE

Action of Board On: 09/20/2022

APPROVED AS RECOMMENDED

OTHER

Clerks Notes:

VOTE OF SUPERVISORS

AYE:

John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor

ABSENT:

Diane Burgis, District III Supervisor

Contact:

Sam Ferrell, (925) 357-7483

I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED: September 20, 2022
Monica Nino, County Administrator

BY:	, Deputy

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent or designee to execute, on behalf of the Health Services Director, a Purchase Order with Polymedco, Inc., in an amount not to exceed $1,200,000 to purchase reagents and supplies to perform immunochemical fecal occult blood testing (FOBT) for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC) for the period from October 1, 2022, through September 30, 2025.

FISCAL IMPACT:

Approval of this action will result in expenditures of up to $1,200,000 over the three-year period between October 1, 2022 through September 30, 2025 and will be funded 100% by the Hospital Enterprise Fund I revenues.

BACKGROUND:

Polymedco, Inc.’s OC-Auto Micro 80 Analyzer with FOBT-CHECK is an automated immunochemical fecal occult blood testing system that detects human red cells only with no interferences from red meat, turnips, melons, aspirin, anti-inflammatory drugs, and vitamin C. This improvement directs many more of the “right” patients to colonoscopy leading to the earlier detection of polyps and colorectal cancer. The increased sensitivity and specifics of this test over the current method is expected to improve detection of early-stage colon cancer, which currently is the third most common cancer and the second leading cause of cancer deaths in the U.S. at 30%. The increased specificity results in fewer false positives, allowing the correct identification of those patients who need expensive colonoscopy procedures. Replacing the sigmoidoscopy and colonoscopy with this lab test for cancer screening will significantly reduce the overall cost to the organization.

On August 6, 2019, the Board approved agenda item C.77 to execute a purchase order with Polymedco, Inc., in an amount not to exceed $600,000 for the period of October 1, 2019 through September 30, 2022.

On June 21, 2022, the Board approved agenda item C.97 to execute an amendment to purchase order #16899 with Polymedco, Inc., to increase the payment limit by $150,000 to a new payment limit of $750,000 with no change to the original term of October 1, 2019 through September 30, 2022.

Polymedco, Inc. provides reagents and supplies to perform immunochemical fecal occult blood testing (FOBT) for Polymedco, Inc.’s OC-Auto Micro 80 Analyzer with FOBT-CHECK, therefore a sole source justification was completed.

Approval of this purchase order request will allow the department to continue purchasing immunochemical fecal occult blood testing reagents and supplies from Polymedco, Inc. through September 30, 2025.

CONSEQUENCE OF NEGATIVE ACTION:

If this purchase rder is not approved, the Clinical Lab will not have the ability to procure the necessary supplies and reagents from Polymedco, Inc. and will be unable to support testing needs for the hospital. This will have a significant negative impact on patient care, as early detection is a key tool for patients to maintain their overall good health. Further, the lab would need to send patient samples out to reference laboratories, which will result in an increase in the cost per test and additional courier fees.